{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T23:11:48Z","timestamp":1723072308830},"reference-count":61,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,28]]},"DOI":"10.7759\/cureus.18349","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T13:57:12Z","timestamp":1632837432000},"source":"Crossref","is-referenced-by-count":3,"title":["A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Megha","family":"Suri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nkiruka","family":"Okpaleke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikha","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchitra","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafar","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed  G","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harjeevan  S","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel RL","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021, 71:7-33. 10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061182","article-title":"Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies","volume":"10","author":"Rathore R","year":"2021","unstructured":"Rathore R, Van Tine BA. Pathogenesis and current treatment of osteosarcoma: perspectives for future therapies. J Clin Med. 2021, 10:1182. 10.3390\/jcm10061182","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.05.005","article-title":"Primary bone osteosarcoma in the pediatric age: state of the art","volume":"32","author":"Longhi A","year":"2006","unstructured":"Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006, 32:423-36. 10.1016\/j.ctrv.2006.05.005","journal-title":"Cancer Treat Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32832b1111","article-title":"Bone tumors: osteosarcoma and Ewing's sarcoma","volume":"21","author":"Heare T","year":"2009","unstructured":"Heare T, Hensley MA, Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr. 2009, 21:365-72. 10.1097\/MOP.0b013e32832b1111","journal-title":"Curr Opin Pediatr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-008-0335-z","article-title":"Osteosarcoma development and stem cell differentiation","volume":"466","author":"Tang N","year":"2008","unstructured":"Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res. 2008, 466:2114-30. 10.1007\/s11999-008-0335-z","journal-title":"Clin Orthop Relat Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00181","article-title":"Immunotherapy of childhood sarcomas","volume":"5","author":"Roberts SS","year":"2015","unstructured":"Roberts SS, Chou AJ, Cheung NK. Immunotherapy of childhood sarcomas. Front Oncol. 2015, 5:181. 10.3389\/fonc.2015.00181","journal-title":"Front Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0050-2","article-title":"Osteosarcoma overview","volume":"4","author":"Lindsey BA","year":"2017","unstructured":"Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther. 2017, 4:25-43. 10.1007\/s40744-016-0050-2","journal-title":"Rheumatol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7035045","article-title":"Current and emerging targets in immunotherapy for osteosarcoma","volume":"2019","author":"Miwa S","year":"2019","unstructured":"Miwa S, Shirai T, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Current and emerging targets in immunotherapy for osteosarcoma. J Oncol. 2019, 2019:7035045. 10.1155\/2019\/7035045","journal-title":"J Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_175378","article-title":"Advances in the treatment of pediatric bone sarcomas","volume":"37","author":"Grohar PJ","year":"2017","unstructured":"Grohar PJ, Janeway KA, Mase LD, Schiffman JD. Advances in the treatment of pediatric bone sarcomas. Am Soc Clin Oncol Educ Book. 2017, 37:725-35. 10.1200\/EDBK_175378","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0756-z","article-title":"Emerging trends in immunotherapy for pediatric sarcomas","volume":"12","author":"Dyson KA","year":"2019","unstructured":"Dyson KA, Stover BD, Grippin A, Mendez-Gomez HR, Lagmay J, Mitchell DA, Sayour EJ. Emerging trends in immunotherapy for pediatric sarcomas. J Hematol Oncol. 2019, 12:78. 10.1186\/s13045-019-0756-z","journal-title":"J Hematol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00353","article-title":"T-cell-based immunotherapy for osteosarcoma: challenges and opportunities","volume":"7","author":"Wang Z","year":"2016","unstructured":"Wang Z, Li B, Ren Y, Ye Z. T-cell-based immunotherapy for osteosarcoma: challenges and opportunities. Front Immunol. 2016, 7:353. 10.3389\/fimmu.2016.00353","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4015039","article-title":"The immunomodulatory effects of mesenchymal stem cell polarization within the tumor microenvironment niche","volume":"2017","author":"Rivera-Cruz CM","year":"2017","unstructured":"Rivera-Cruz CM, Shearer JJ, Figueiredo Neto M, Figueiredo ML. The immunomodulatory effects of mesenchymal stem cell polarization within the tumor microenvironment niche. Stem Cells Int. 2017, 2017:4015039. 10.1155\/2017\/4015039","journal-title":"Stem Cells Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0025","article-title":"Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas","volume":"23","author":"Nathenson MJ","year":"2018","unstructured":"Nathenson MJ, Conley AP, Sausville E. Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas. Oncologist. 2018, 23:71-83. 10.1634\/theoncologist.2016-0025","journal-title":"Oncologist"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-018-0297-x","article-title":"Pediatric cancer immunotherapy: opportunities and challenges","volume":"20","author":"Wedekind MF","year":"2018","unstructured":"Wedekind MF, Denton NL, Chen CY, Cripe TP. Pediatric cancer immunotherapy: opportunities and challenges. Paediatr Drugs. 2018, 20:395-408. 10.1007\/s40272-018-0297-x","journal-title":"Paediatr Drugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang W","year":"2020","unstructured":"Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020, 53:e12712. 10.1111\/cpr.12712","journal-title":"Cell Prolif"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0692","article-title":"Immunotherapy of pediatric solid tumors: treatments at a crossroads, with an emphasis on antibodies","volume":"8","author":"Casey DL","year":"2020","unstructured":"Casey DL, Cheung NV. Immunotherapy of pediatric solid tumors: treatments at a crossroads, with an emphasis on antibodies. Cancer Immunol Res. 2020, 8:161-6. 10.1158\/2326-6066.CIR-19-0692","journal-title":"Cancer Immunol Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001580","article-title":"Immunotherapy for sarcomas: new frontiers and unveiled opportunities","volume":"9","author":"Birdi HK","year":"2021","unstructured":"Birdi HK, Jirovec A, Cort\u00e9s-Kaplan S, Werier J, Nessim C, Diallo JS, Ardolino M. Immunotherapy for sarcomas: new frontiers and unveiled opportunities. J Immunother Cancer. 2021, 9:e001580. 10.1136\/jitc-2020-001580","journal-title":"J Immunother Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023251","article-title":"Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients","volume":"99","author":"Zhang Z","year":"2020","unstructured":"Zhang Z, Liu C, Liang T, et al.. Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients. Medicine (Baltimore). 2020, 99:e23251. 10.1097\/MD.0000000000023251","journal-title":"Medicine (Baltimore)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02829-y","article-title":"Is immunotherapy in the future of therapeutic management of sarcomas?","volume":"19","author":"Clemente O","year":"2021","unstructured":"Clemente O, Ottaiano A, Di Lorenzo G, et al.. Is immunotherapy in the future of therapeutic management of sarcomas?. J Transl Med. 2021, 19:173. 10.1186\/s12967-021-02829-y","journal-title":"J Transl Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609762","article-title":"Reprogramming immune cells for enhanced cancer immunotherapy: targets and strategies","volume":"12","author":"Dong Y","year":"2021","unstructured":"Dong Y, Wan Z, Gao X, Yang G, Liu L. Reprogramming immune cells for enhanced cancer immunotherapy: targets and strategies. Front Immunol. 2021, 12:609762. 10.3389\/fimmu.2021.609762","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081757","article-title":"Systematic review of recurrent osteosarcoma systemic therapy","volume":"13","author":"Gazouli I","year":"2021","unstructured":"Gazouli I, Kyriazoglou A, Kotsantis I, et al.. Systematic review of recurrent osteosarcoma systemic therapy. Cancers (Basel). 2021, 13:1757. 10.3390\/cancers13081757","journal-title":"Cancers (Basel)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0576","article-title":"Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma","volume":"78","author":"Scott MC","year":"2018","unstructured":"Scott MC, Temiz NA, Sarver AE, et al.. Comparative transcriptome analysis quantifies immune cell transcript levels, metastatic progression, and survival in osteosarcoma. Cancer Res. 2018, 78:326-37. 10.1158\/0008-5472.CAN-17-0576","journal-title":"Cancer Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)90001-7","article-title":"Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity","volume":"90","author":"Smyth MJ","year":"2006","unstructured":"Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006, 90:1-50. 10.1016\/S0065-2776(06)90001-7","journal-title":"Adv Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel CM","year":"2007","unstructured":"Koebel CM, Vermi W, Swann JB, et al.. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007, 450:903-7. 10.1038\/nature06309","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2007-0594","article-title":"Concise review: isolation and characterization of cells from human term placenta: outcome of the First International Workshop on Placenta Derived Stem Cells","volume":"26","author":"Parolini O","year":"2008","unstructured":"Parolini O, Alviano F, Bagnara GP, et al.. Concise review: isolation and characterization of cells from human term placenta: outcome of the First International Workshop on Placenta Derived Stem Cells. Stem Cells. 2008, 26:300-11. 10.1634\/stemcells.2007-0594","journal-title":"Stem Cells"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040506","article-title":"Present advances and future perspectives of molecular targeted therapy for osteosarcoma","volume":"17","author":"Shaikh AB","year":"2016","unstructured":"Shaikh AB, Li F, Li M, et al.. Present advances and future perspectives of molecular targeted therapy for osteosarcoma. Int J Mol Sci. 2016, 17:506. 10.3390\/ijms17040506","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade","volume":"24","author":"Nowicki TS","year":"2018","unstructured":"Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 2018, 24:47-53. 10.1097\/PPO.0000000000000303","journal-title":"Cancer J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21155","article-title":"CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction","volume":"117","author":"Contardi E","year":"2005","unstructured":"Contardi E, Palmisano GL, Tazzari PL, et al.. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer. 2005, 117:538-50. 10.1002\/ijc.21155","journal-title":"Int J Cancer"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0067-z","article-title":"Combination immunotherapy with \u03b1-CTLA-4 and \u03b1-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma","volume":"3","author":"Lussier DM","year":"2015","unstructured":"Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination immunotherapy with \u03b1-CTLA-4 and \u03b1-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer. 2015, 3:21. 10.1186\/s40425-015-0067-z","journal-title":"J Immunother Cancer"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0491","article-title":"Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors","volume":"22","author":"Merchant MS","year":"2016","unstructured":"Merchant MS, Wright M, Baird K, et al.. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016, 22:1364-70. 10.1158\/1078-0432.CCR-15-0491","journal-title":"Clin Cancer Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi HA","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, et al.. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017, 18:1493-501. 10.1016\/S1470-2045(17)30624-1","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4829-0","article-title":"Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma","volume":"18","author":"Keung EZ","year":"2018","unstructured":"Keung EZ, Lazar AJ, Torres KE, et al.. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. BMC Cancer. 2018, 18:913. 10.1186\/s12885-018-4829-0","journal-title":"BMC Cancer"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02876-w","article-title":"Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial","volume":"70","author":"Boye K","year":"2021","unstructured":"Boye K, Longhi A, Guren T, et al.. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother. 2021, 70:2617-24. 10.1007\/s00262-021-02876-w","journal-title":"Cancer Immunol Immunother"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis KL","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, et al.. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020, 21:541-50. 10.1016\/S1470-2045(20)30023-1","journal-title":"Lancet Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040886","article-title":"Unmet medical needs and future perspectives for leiomyosarcoma patients-a position paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)","volume":"13","author":"Kasper B","year":"2021","unstructured":"Kasper B, Achee A, Schuster K, et al.. Unmet medical needs and future perspectives for leiomyosarcoma patients-a position paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers (Basel). 2021, 13:886. 10.3390\/cancers13040886","journal-title":"Cancers (Basel)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.0670","article-title":"Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma","volume":"29","author":"Juergens H","year":"2011","unstructured":"Juergens H, Daw NC, Geoerger B, et al.. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011, 29:4534-40. 10.1200\/JCO.2010.33.0670","journal-title":"J Clin Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70049-4","article-title":"Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial","volume":"14","author":"Schwartz GK","year":"2013","unstructured":"Schwartz GK, Tap WD, Qin LX, et al.. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013, 14:371-82. 10.1016\/S1470-2045(13)70049-4","journal-title":"Lancet Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.009","article-title":"Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas","volume":"48","author":"Asmane I","year":"2012","unstructured":"Asmane I, Watkin E, Alberti L, et al.. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer. 2012, 48:3027-35. 10.1016\/j.ejca.2012.05.009","journal-title":"Eur J Cancer"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2364","article-title":"Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing","volume":"20","author":"Turner DC","year":"2014","unstructured":"Turner DC, Navid F, Daw NC, et al.. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res. 2014, 20:2783-92. 10.1158\/1078-0432.CCR-13-2364","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.08.015","article-title":"Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the Children's Oncology Group","volume":"121","author":"Kopp LM","year":"2019","unstructured":"Kopp LM, Malempati S, Krailo M, et al.. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the Children's Oncology Group. Eur J Cancer. 2019, 121:177-83. 10.1016\/j.ejca.2019.08.015","journal-title":"Eur J Cancer"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.1055","article-title":"Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors","volume":"30","author":"Merchant MS","year":"2012","unstructured":"Merchant MS, Geller JI, Baird K, et al.. Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol. 2012, 30:4141-7. 10.1200\/JCO.2012.44.1055","journal-title":"J Clin Oncol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.116","article-title":"Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know","volume":"8","author":"Rosenberg SA","year":"2011","unstructured":"Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nat Rev Clin Oncol. 2011, 8:577-85. 10.1038\/nrclinonc.2011.116","journal-title":"Nat Rev Clin Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg SA","year":"2015","unstructured":"Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015, 348:62-8. 10.1126\/science.aaa4967","journal-title":"Science"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.987121","article-title":"Adoptive immunotherapy against sarcomas","volume":"15","author":"Mesiano G","year":"2015","unstructured":"Mesiano G, Leuci V, Giraudo L, et al.. Adoptive immunotherapy against sarcomas. Expert Opin Biol Ther. 2015, 15:517-28. 10.1517\/14712598.2015.987121","journal-title":"Expert Opin Biol Ther"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.5092","article-title":"Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens","volume":"167","author":"Kato Y","year":"2001","unstructured":"Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N. Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol. 2001, 167:5092-8. 10.4049\/jimmunol.167.9.5092","journal-title":"J Immunol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/jor.21579","article-title":"Sensitization of human osteosarcoma cells to V\u03b39V\u03b42 T-cell-mediated cytotoxicity by zoledronate","volume":"30","author":"Li Z","year":"2012","unstructured":"Li Z, Peng H, Xu Q, Ye Z. Sensitization of human osteosarcoma cells to V\u03b39V\u03b42 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res. 2012, 30:824-30. 10.1002\/jor.21579","journal-title":"J Orthop Res"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2019.04.006","article-title":"CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs","volume":"141","author":"Rahbarizadeh F","year":"2019","unstructured":"Rahbarizadeh F, Ahmadvand D, Moghimi SM. CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Adv Drug Deliv Rev. 2019, 141:41-6. 10.1016\/j.addr.2019.04.006","journal-title":"Adv Drug Deliv Rev"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0405-3","article-title":"Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies","volume":"10","author":"Liu J","year":"2017","unstructured":"Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017, 10:35. 10.1186\/s13045-017-0405-3","journal-title":"J Hematol Oncol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2011.573476","article-title":"Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy","volume":"11","author":"Ramos CA","year":"2011","unstructured":"Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011, 11:855-73. 10.1517\/14712598.2011.573476","journal-title":"Expert Opin Biol Ther"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) - specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed N","year":"2015","unstructured":"Ahmed N, Brawley VS, Hegde M, et al.. Human epidermal growth factor receptor 2 (HER2) - specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015, 33:1688-96. 10.1200\/JCO.2014.58.0225","journal-title":"J Clin Oncol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde M","year":"2020","unstructured":"Hegde M, Joseph SK, Pashankar F, et al.. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020, 11:3549. 10.1038\/s41467-020-17175-8","journal-title":"Nat Commun"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3282f43acf","article-title":"Ganglioside signatures of primary and nodal metastatic melanoma cell lines from the same patient","volume":"18","author":"Ravindranath MH","year":"2008","unstructured":"Ravindranath MH, Muthugounder S, Presser N. Ganglioside signatures of primary and nodal metastatic melanoma cell lines from the same patient. Melanoma Res. 2008, 18:47-55. 10.1097\/CMR.0b013e3282f43acf","journal-title":"Melanoma Res"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910490616","article-title":"Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. EORTC Cooperative Melanoma Group","volume":"49","author":"Portoukalian J","year":"1991","unstructured":"Portoukalian J, Carrel S, Dor\u00e9 JF, R\u00fcmke P. Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. EORTC Cooperative Melanoma Group. Int J Cancer. 1991, 49:893-9. 10.1002\/ijc.2910490616","journal-title":"Int J Cancer"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0548-2","article-title":"Anti-GD2\/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients","volume":"11","author":"Yu J","year":"2018","unstructured":"Yu J, Wu X, Yan J, et al.. Anti-GD2\/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. J Hematol Oncol. 2018, 11:1. 10.1186\/s13045-017-0548-2","journal-title":"J Hematol Oncol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2017.07.009","article-title":"NK cell-based immunotherapy for cancer","volume":"31","author":"Fang F","year":"2017","unstructured":"Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol. 2017, 31:37-54. 10.1016\/j.smim.2017.07.009","journal-title":"Semin Immunol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.05.015","article-title":"Anticancer cytokines: biology and clinical effects of interferon-\u03b12, interleukin (IL)-2, IL-15, IL-21, and IL-12","volume":"42","author":"Floros T","year":"2015","unstructured":"Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-\u03b12, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015, 42:539-48. 10.1053\/j.seminoncol.2015.05.015","journal-title":"Semin Oncol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2011.07.311","article-title":"Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes","volume":"72","author":"Pillet AH","year":"2011","unstructured":"Pillet AH, Th\u00e8ze J, Rose T. Interleukin (IL)-2 and IL-15 have different effects on human natural killer lymphocytes. Hum Immunol. 2011, 72:1013-7. 10.1016\/j.humimm.2011.07.311","journal-title":"Hum Immunol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0965-3","article-title":"Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells","volume":"60","author":"Buddingh EP","year":"2011","unstructured":"Buddingh EP, Schilham MW, Ruslan SE, et al.. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. Cancer Immunol Immunother. 2011, 60:575-86. 10.1007\/s00262-010-0965-3","journal-title":"Cancer Immunol Immunother"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.125","article-title":"Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy","volume":"39","author":"Hu Y","year":"2018","unstructured":"Hu Y, Tian ZG, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018, 39:167-76. 10.1038\/aps.2017.125","journal-title":"Acta Pharmacol Sin"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.07.004","article-title":"Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors","volume":"40","author":"P\u00e9rez-Mart\u00ednez A","year":"2012","unstructured":"P\u00e9rez-Mart\u00ednez A, de Prada Vicente I, Fern\u00e1ndez L, et al.. Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. Exp Hematol. 2012, 40:882-91. 10.1016\/j.exphem.2012.07.004","journal-title":"Exp Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/68113-a-deep-dive-into-the-newest-avenues-of-immunotherapy-for-pediatric-osteosarcoma-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:34:32Z","timestamp":1707507272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/68113-a-deep-dive-into-the-newest-avenues-of-immunotherapy-for-pediatric-osteosarcoma-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":61,"URL":"https:\/\/doi.org\/10.7759\/cureus.18349","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}